2024
The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer
Johnson K, Ni A, Quiroga D, Pariser A, Sudheendra P, Williams N, Sardesai S, Cherian M, Stover D, Gatti-Mays M, Ramaswamy B, Lustberg M, Jhawar S, Skoracki R, Wesolowski R. The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer. Npj Breast Cancer 2024, 10: 49. PMID: 38898072, PMCID: PMC11187074, DOI: 10.1038/s41523-024-00652-4.Peer-Reviewed Original ResearchInvasive disease-free survivalHER2+ breast cancerAdjuvant trastuzumabOverall survivalLocoregional therapyUnivariate analysisBreast cancerBenefit of adjuvant trastuzumabBenefits of adjuvant systemic therapyMulti-institutional retrospective analysisAdjuvant systemic therapyCompare survival outcomesDisease-free survivalTrastuzumab monotherapyNode-negativeSystemic therapyCombination therapySurvival benefitStatistically significant improvementSurvival outcomesRetrospective analysisMultivariate analysisPrimary outcomeTrastuzumabTherapy
2015
Risk factors for anthracycline-associated cardiotoxicity
Reinbolt R, Patel R, Pan X, Timmers C, Pilarski R, Shapiro C, Lustberg M. Risk factors for anthracycline-associated cardiotoxicity. Supportive Care In Cancer 2015, 24: 2173-2180. PMID: 26563179, PMCID: PMC4874738, DOI: 10.1007/s00520-015-3008-y.Peer-Reviewed Original ResearchConceptsSingle nucleotide polymorphismsAnthracycline cardiotoxicityRisk factorsAlcoholic drinks/weekFemale breast cancer patientsHigher cardiotoxicity riskDrinks/weekModerate alcohol consumptionAnthracycline-associated cardiotoxicityBreast cancer patientsCases of cardiotoxicityMajor alleleEjection fractionPediatric patientsCancer patientsCardiotoxicity riskLower riskTherapeutic strategiesAlcohol consumptionCardiotoxicityMultivariate analysisLogistic regressionPatientsGenomic predictorsSignificant correlation